Which of the following is a known side effect of zidovudine?
Which of the following drug combinations demonstrates antimicrobial synergism?
What is the drug of choice for neurocysticercosis?
Ethambutol is safer in a patient with which of the following conditions?
Bictegravir was approved by FDA for which of the following indications?
All of the following are drugs used for the treatment of tuberculosis except?
Which of the following is a neuraminidase inhibitor?
The oropharyngeal and oesophageal candidiasis following long-term therapy with a broad-spectrum antibiotic can be best treated with?
Which of the following antimicrobial agents does not act by inhibiting cell wall synthesis?
What are the drugs of choice for the treatment of neurocysticercosis?
Explanation: Zidovudine (AZT) is a Nucleoside Reverse Transcriptase Inhibitor (NRTI) used in the management of HIV/AIDS. The correct answer is Granulocytopenia because the most significant and dose-limiting toxicity of zidovudine is bone marrow suppression. 1. Why Granulocytopenia is correct: Zidovudine inhibits DNA polymerase-gamma in host cells, leading to mitochondrial toxicity and interference with rapidly dividing cells [1], [2]. This results in significant myelosuppression, manifesting primarily as anemia (macrocytic) and granulocytopenia/neutropenia. This effect is additive when used with other myelosuppressive drugs like ganciclovir or trimethoprim-sulfamethoxazole. 2. Why other options are incorrect: * Headache and Myalgia (Options A & B): While these can occur as non-specific constitutional symptoms during the initiation of therapy, they are not the "signature" or dose-limiting toxicities tested in competitive exams. (Note: Zidovudine causes a specific myopathy, but granulocytopenia is the more classic hematological side effect). * Rashes (Option D): Rashes are more characteristic of Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) like Nevirapine (which can cause Stevens-Johnson Syndrome) or the NRTI Abacavir (hypersensitivity reaction). High-Yield Clinical Pearls for NEET-PG: * Mnemonic: Zidovudine causes "Zapped" Bone Marrow (Anemia and Neutropenia). * Drug of Choice: Zidovudine is the preferred drug for preventing vertical transmission (mother-to-child) of HIV during pregnancy and labor. * Lactic Acidosis: Like all NRTIs, it carries a risk of lactic acidosis and hepatic steatosis [2]. * Monitoring: Patients on AZT require regular monitoring of Hemoglobin and Absolute Neutrophil Count (ANC).
Explanation: **Explanation:** **1. Why Option A is Correct (The Concept of Synergism):** The combination of **Penicillin and Streptomycin** is a classic example of **sequential blockade** leading to bactericidal synergism. Penicillin, a cell wall synthesis inhibitor, damages the bacterial cell wall. This increased permeability allows Streptomycin (an aminoglycoside) to enter the cell more easily and reach its target site (the 30S ribosome) to inhibit protein synthesis. This synergy is clinically vital in treating **Enterococcal Subacute Bacterial Endocarditis (SABE)**, where either drug alone would only be bacteriostatic or ineffective. **2. Analysis of Other Options:** * **Option B (Ampicillin + Tetracycline):** This is an example of **Antagonism**. Ampicillin (bactericidal) requires actively multiplying bacteria to work. Tetracycline (bacteriostatic) inhibits growth, thereby reducing the efficacy of the penicillin. * **Option C & D:** While these combinations are indeed synergistic (Sequential blockade in Cotrimoxazole; increased uptake in Amphotericin + Flucytosine), the question asks for the **most definitive** example of antimicrobial synergism traditionally taught in the context of endocarditis and cell-wall/protein-synthesis interaction. *Note: In many exams, if multiple options show synergism, the Penicillin + Aminoglycoside pair is considered the "gold standard" answer for this concept.* **3. NEET-PG High-Yield Pearls:** * **Synergism Mechanisms:** 1. **Sequential Blockade:** Sulfonamides + Trimethoprim. 2. **Facilitation of entry:** Penicillins + Aminoglycosides. 3. **Inhibition of degrading enzymes:** Amoxicillin + Clavulanic acid. * **Rule of Thumb:** Bactericidal + Bactericidal = Synergistic; Bactericidal + Bacteriostatic = Antagonistic. * **Clinical Exception:** In Meningitis, combinations are used to expand coverage, not necessarily for synergism.
Explanation: **Explanation:** **Albendazole** is the drug of choice for neurocysticercosis (NCC) caused by the larval stage of *Taenia solium*. The primary reason for its superiority over other agents is its **superior penetration into the Central Nervous System (CNS)**. Albendazole is a prodrug converted to albendazole sulfoxide, which achieves high concentrations in the cerebrospinal fluid (CSF) and brain parenchyma. It is more effective than Praziquantel in reducing the number of viable cysts and controlling seizures, especially in parenchymal NCC. **Analysis of Options:** * **Praziquantel (Option A):** While effective against many trematodes and cestodes, it has lower CNS penetration compared to Albendazole. It is considered a second-line agent or used in combination with Albendazole for heavy cyst burdens (multicystic disease). * **Levamisole (Option C):** Primarily used as an immunomodulator or for Ascaris infections; it has no role in treating NCC. * **Piperazine (Option D):** An older anthelmintic used for *Ascaris* and *Enterobius* by causing flaccid paralysis of the worm; it is ineffective against cysticercosis. **Clinical Pearls for NEET-PG:** 1. **Steroid Co-administration:** Always administer corticosteroids (e.g., Dexamethasone) before or with Albendazole to prevent inflammatory brain edema caused by the death of the larvae (Herxheimer-like reaction). 2. **Duration:** Treatment typically lasts 8–15 days for parenchymal cysts. 3. **Ocular Cysticercosis:** Albendazole is **contraindicated** in ocular cysticercosis as the inflammatory response to dying larvae can cause permanent blindness. Surgical excision is preferred. 4. **Mechanism:** Albendazole works by inhibiting microtubule synthesis (binding to β-tubulin), leading to glucose depletion and death of the parasite.
Explanation: **Explanation:** The correct answer is **Liver disease** because Ethambutol is primarily excreted unchanged by the kidneys (approx. 80%) and undergoes minimal hepatic metabolism. Unlike other first-line anti-tubercular drugs (HRZ—Isoniazid, Rifampicin, and Pyrazinamide), Ethambutol is **not hepatotoxic**. Therefore, it is the drug of choice or a safer alternative when treating tuberculosis in patients with pre-existing chronic liver disease. **Analysis of Incorrect Options:** * **Kidney disease:** Since Ethambutol is mainly excreted via the renal route, it accumulates in renal failure, increasing the risk of dose-dependent toxicity (optic neuritis). Dosage adjustment or avoidance is necessary in renal impairment. * **Gout:** Ethambutol interferes with the renal excretion of uric acid, leading to **hyperuricemia**. This can precipitate an acute attack of gout, making it unsafe for these patients. * **Both liver and kidney disease:** While safe for the liver, its significant risk in renal failure makes this option incorrect. **High-Yield NEET-PG Pearls:** * **Mechanism of Action:** Inhibits **Arabinosyl transferase**, thereby blocking the synthesis of Arabinogalactan in the mycobacterial cell wall. * **Key Side Effect:** **Retrobulbar Optic Neuritis**, manifesting as decreased visual acuity and **Red-Green color blindness**. It is generally reversible upon discontinuation. * **Monitoring:** Monthly visual acuity and color vision testing are mandatory for patients on Ethambutol. * **Pediatric Note:** It is often avoided in young children (usually <6 years) because they cannot reliably report changes in visual acuity or color perception.
Explanation: **Explanation:** **Bictegravir** is a potent, second-generation **Integrase Strand Transfer Inhibitor (INSTI)**. It was FDA-approved in 2018 as part of a fixed-dose combination (Bictegravir/Emtricitabine/Tenofovir Alafenamide) for the treatment of **HIV-1 infection** in both treatment-naïve and virologically suppressed patients. **Mechanism of Action:** Bictegravir works by binding to the integrase active site and blocking the strand transfer step of retroviral DNA integration into the host cell genome. This prevents the HIV-1 provirus from replicating. **Analysis of Incorrect Options:** * **A. Cystic Fibrosis:** This is a genetic disorder affecting chloride channels (CFTR). Treatment involves CFTR modulators (e.g., Ivacaftor) and antibiotics for lung infections, but not antiretrovirals. * **B. Tuberculosis:** TB is caused by *Mycobacterium tuberculosis* and is treated with RIPE therapy (Rifampin, Isoniazid, Pyrazinamide, Ethambutol). While HIV and TB are common co-infections, Bictegravir itself has no anti-mycobacterial activity. * **C. Hypertension:** This is managed with ACE inhibitors, ARBs, Beta-blockers, or Calcium channel blockers. **High-Yield Clinical Pearls for NEET-PG:** * **Class:** INSTI (Suffix "-tegravir"). Other members include Dolutegravir, Raltegravir, and Elvitegravir. * **Advantages:** Bictegravir has a **high genetic barrier to resistance** and fewer drug-drug interactions compared to older protease inhibitors or Elvitegravir (which requires boosting with Cobicistat). * **Side Effects:** Generally well-tolerated; may cause headache, GI upset, or weight gain. * **Drug Interaction:** Avoid co-administration with polyvalent cations (Mg, Al, Ca) as they can chelate the drug and reduce absorption.
Explanation: **Explanation:** The correct answer is **C. 5-flucytosine**. **1. Why 5-flucytosine is the correct answer:** 5-flucytosine (Flucytosine) is an **antifungal agent**, not an antitubercular drug. It is a pyrimidine antimetabolite that inhibits DNA and RNA synthesis in fungi. It is primarily used in combination with Amphotericin B for treating systemic fungal infections, most notably **Cryptococcal meningitis**. It has no activity against *Mycobacterium tuberculosis*. **2. Analysis of incorrect options (Antitubercular Drugs):** * **Kanamycin (Option A):** This is an aminoglycoside antibiotic. It is classified as a **Second-line injectable** antitubercular drug (Group B in older WHO classifications) [1]. It inhibits protein synthesis by binding to the 30S ribosomal subunit. * **Cycloserine (Option B):** This is a bacteriostatic **Second-line oral** antitubercular drug [1]. It inhibits bacterial cell wall synthesis by acting as an analog of D-alanine [2]. It is known for its significant CNS side effects (neuropsychiatric symptoms). * **Ofloxacin (Option D):** This is a second-generation **Fluoroquinolone**. Fluoroquinolones (like Levofloxacin and Moxifloxacin) are potent second-line agents used in the treatment of Multi-Drug Resistant TB (MDR-TB) [1]. **3. NEET-PG High-Yield Pearls:** * **WHO Classification Update:** Modern MDR-TB regimens prioritize **Group A** drugs: Levofloxacin/Moxifloxacin, Bedaquiline, and Linezolid. * **Newer Drugs:** Bedaquiline (inhibits ATP synthase) and Delamanid (inhibits mycolic acid synthesis) are frequently tested. * **Cycloserine Side Effects:** Often managed with **Pyridoxine (Vitamin B6)** to reduce neurological toxicity. * **5-Flucytosine Toxicity:** The most common dose-limiting toxicity is **bone marrow suppression** (anemia, leukopenia, thrombocytopenia).
Explanation: **Explanation:** **Correct Answer: A. Oseltamivir** Oseltamivir is a **Neuraminidase Inhibitor** used for the treatment and prophylaxis of Influenza A and B. Neuraminidase is a viral enzyme responsible for cleaving sialic acid residues on the host cell surface. By inhibiting this enzyme, Oseltamivir prevents the release of newly formed virions from infected cells, thereby limiting the spread of infection within the respiratory tract. It is administered orally as a prodrug. **Analysis of Incorrect Options:** * **B. Amantadine:** This is an **M2 ion channel blocker**. It prevents the "uncoating" of the Influenza A virus. It is ineffective against Influenza B and is currently rarely used due to widespread resistance. * **C. Enfuvirtide:** This is a **Fusion Inhibitor** used in HIV/AIDS. It binds to the gp41 subunit of the viral envelope glycoprotein, preventing the virus from fusing with the host CD4 cell membrane. * **D. Fomivirsen:** This is an **Antisense Oligonucleotide**. It was used (now discontinued) for the intravitreal treatment of CMV retinitis. It works by binding to viral mRNA to inhibit protein synthesis. **High-Yield NEET-PG Pearls:** * **Zanamivir** is another neuraminidase inhibitor but is administered via **inhalation** (contraindicated in asthma/COPD due to bronchospasm). * **Peramivir** is the IV neuraminidase inhibitor used for emergency/severe cases. * **Baloxavir Marboxil** is a newer drug for Influenza that inhibits **Cap-dependent Endonuclease**, blocking viral RNA synthesis. * Oseltamivir must be started within **48 hours** of symptom onset for maximum clinical benefit.
Explanation: **Explanation:** The clinical scenario describes **Opportunistic Candidiasis** (Oropharyngeal and Oesophageal) resulting from the suppression of normal protective bacterial flora by broad-spectrum antibiotics. **Why Fluconazole is the Correct Answer:** Fluconazole is the **drug of choice** for both oropharyngeal and oesophageal candidiasis. It is a triazole antifungal that inhibits the enzyme *14-alpha-demethylase*, preventing the synthesis of ergosterol. It is preferred because of its **excellent oral bioavailability**, high efficacy, and superior safety profile compared to older antifungals. For oesophageal involvement (which is considered a systemic/deep infection), systemic therapy with Fluconazole is mandatory. **Analysis of Incorrect Options:** * **A. Griseofulvin:** This is an antifungal used exclusively for **Dermatophytosis** (skin, hair, and nail infections). It is completely ineffective against *Candida* species. * **B. Amphotericin B:** While highly effective against *Candida*, it is reserved for **severe, refractory, or life-threatening systemic fungal infections** due to its significant nephrotoxicity and requirement for intravenous administration. It is not the first-line treatment for uncomplicated mucosal candidiasis. * **D. Sulfonates:** These are not standard antifungal agents used for treating mucosal candidiasis. **NEET-PG High-Yield Pearls:** * **Drug of Choice (DOC):** For Oropharyngeal Candidiasis (Thrush) in HIV/Immunocompromised patients is **Fluconazole**. * **Vaginal Candidiasis:** A single 150 mg oral dose of Fluconazole is the standard treatment. * **Resistance:** *Candida krusei* and *Candida glabrata* often show inherent or acquired resistance to Fluconazole; in such cases, Echinocandins (e.g., Caspofungin) or Voriconazole are used. * **Side Effect:** Fluconazole is a known inhibitor of CYP450 enzymes, leading to potential drug interactions (e.g., increasing Warfarin or Phenytoin levels).
Explanation: ### Explanation The correct answer is **A. Aminoglycoside**. *(Note: There appears to be a discrepancy in the provided key. While Bacitracin inhibits cell wall synthesis, Aminoglycosides inhibit protein synthesis. Below is the medically accurate explanation for NEET-PG.)* #### 1. Why Aminoglycosides are the Correct Choice Antimicrobial agents are classified based on their mechanism of action. **Aminoglycosides** (e.g., Gentamicin, Amikacin, Streptomycin) act by binding to the **30S ribosomal subunit**, thereby inhibiting **protein synthesis**. They cause misreading of mRNA and interfere with the initiation complex. Unlike most protein synthesis inhibitors which are bacteriostatic, aminoglycosides are uniquely **bactericidal**. #### 2. Why the Other Options are Incorrect The following drugs all inhibit cell wall synthesis but at different stages: * **Penicillins (B):** These are Beta-lactams that inhibit **transpeptidation** (the final step of cross-linking) by binding to Penicillin-Binding Proteins (PBPs). * **Cycloserine (C):** A structural analog of D-alanine, it inhibits **L-alanine racemase**, preventing the formation of the D-ala-D-ala dipeptide early in peptidoglycan synthesis. * **Bacitracin (D):** It inhibits the **dephosphorylation of the lipid carrier** (bactoprenol), which prevents the transport of peptidoglycan precursors across the cell membrane. #### 3. High-Yield Clinical Pearls for NEET-PG * **Sequential Steps of Cell Wall Inhibition:** * **Cytoplasm:** Cycloserine, Fosfomycin. * **Cell Membrane (Transport):** Bacitracin. * **Cell Wall (Cross-linking):** Penicillins, Cephalosporins, Vancomycin (binds to D-ala-D-ala). * **Aminoglycoside Rule of 3:** They are **A**erobic (require O2 for uptake), **A**nephrotoxic/Ototoxic, and act on the **A**minoacyl site of the 30S ribosome. * **Vancomycin** is often confused with Bacitracin; remember that Vancomycin inhibits **transglycosylation** and prevents elongation of the peptidoglycan chain.
Explanation: **Explanation:** Neurocysticercosis (NCC), caused by the larval stage of the pork tapeworm *Taenia solium*, is a leading cause of adult-onset seizures in developing countries. The management depends on the stage and number of cysts. **Why Albendazole and Praziquantel are correct:** * **Albendazole:** It is the primary anthelmintic of choice due to its superior penetration into the cerebrospinal fluid (CSF) and brain parenchyma. It inhibits microtubule synthesis in the parasite. * **Praziquantel:** It increases the permeability of the parasite cell membrane to calcium, causing paralysis. * **Combination Therapy:** For patients with multiple viable parenchymal cysts (>2 cysts), the combination of Albendazole and Praziquantel is more effective than monotherapy in achieving complete cyst resolution. * *Note:* Corticosteroids (e.g., Dexamethasone) are always co-administered to reduce the inflammatory response triggered by dying parasites. **Why other options are incorrect:** * **Option A & B:** **Metronidazole** is an antiprotozoal/antibiotic used for anaerobic infections and amoebiasis. **Hydroquinone** is a skin-bleaching agent. **Pyrantel pamoate** is used for luminal helminthes (like pinworms) and has poor systemic absorption. * **Option D:** **Cyclophosphamide** is an alkylating cytotoxic chemotherapy agent/immunosuppressant, irrelevant to parasitic infections. **High-Yield Clinical Pearls for NEET-PG:** 1. **Drug of Choice (Single Cyst):** Albendazole monotherapy. 2. **Drug of Choice (Multiple Cysts):** Albendazole + Praziquantel. 3. **Calcified Cysts:** Anthelmintics are NOT required; management is symptomatic (Antiepileptics). 4. **Ocular/Spinal Cysticercosis:** Anthelmintics are generally avoided initially as inflammation can cause irreversible damage (blindness/cord compression). 5. **Pre-treatment:** Always rule out ocular cysticercosis via fundoscopy before starting anthelmintics.
Beta-Lactam Antibiotics
Practice Questions
Aminoglycosides
Practice Questions
Macrolides and Ketolides
Practice Questions
Tetracyclines
Practice Questions
Quinolones
Practice Questions
Sulfonamides and Trimethoprim
Practice Questions
Antimycobacterial Drugs
Practice Questions
Antifungal Agents
Practice Questions
Antiviral Drugs
Practice Questions
Antiparasitic Agents
Practice Questions
Principles of Antimicrobial Selection
Practice Questions
Antimicrobial Resistance
Practice Questions
Get full access to all questions, explanations, and performance tracking.
Start For Free